Pay in 4 interest-free payments of $5.17 Learn more
Ships within 48 hours · Estimated delivery Sep 14 - Sep 19
Strong indicators that you are ready for the next dose step include: GI side effects have fully resolved at the current dose Appetite suppression has stabilized (not increasing or decreasing week to week) Weight loss has slowed or plateaued at the current dose Energy levels are stable and consistent Sleep quality has returned to baseline Indicators that you should hold at the current dose for another cycle include: Persistent nausea beyond the first week at the current dose Digestive issues that have not resolved Weight loss is still progressing well (no need to increase if current dose is working) Energy levels are still adjusting Any concerning symptoms that need medical evaluation The tracking data also helps identify your optimal maintenance dose
If you begin to notice rising hunger, fatigue, or changes in blood sugar, speak with your doctor early
the study participants were 66 years old, on average
In type 2 diabetes populations across 38 phase III/IV trials, the rate was lower at 19.3% versus 6.5% on placebo
Higher risk of contamination or mislabeling Without strict quality controls, compounded drugs can be inconsistent in dosage and purity
As with other agents in the incretin-based injectable class, the most frequently reported side effects of retatrutide in clinical trials have been gastrointestinal in nature
